In this episode of The Oncology Brothers, we discussed the recent approval of Epcoritamab for relapsed refractory follicular lymphoma. Joined by Dr. Gilles Salles from Memorial Sloan Kettering, we dived into the EPCOR FL1 study, which highlighted the combination of Epcoritamab with rituximab and lenalidomide, showcasing significant improvements in progression-free survival (PFS) and overall response rates.
Key topics included:
• The mechanism of action of Epcoritamab as a bispecific antibody targeting CD20 and CD3.
• Study design and findings from the EPCOR FL1 trial.
• Step-up dosing schedule and its implications for patient management.
• Side effects to monitor, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS).
• The role of minimal residual disease (MRD) and ctDNA in treatment decisions.
Join us as we explored the future of treatment options in follicular lymphoma and the potential impact on patient quality of life.
Follow us on social media:
• X/Twitter: https://twitter.com/oncbrothers
• Instagram: https://www.instagram.com/oncbrothers
• Website: https://oncbrothers.com/
Don't forget to like, subscribe, and hit the notification bell for more updates on the latest in oncology!
#Epcoritamab #FollicularLymphoma #BispecificAntibody #CRS #Immunotherapy #OncologyBrothers #Lymphoma
